FDA puts Hemopure trial on hold as it reviews safety

The FDA has put a clinical trial for Biopure's Hemopure therapy on hold saying it needs answers to several safety questions. The Navy has joined with Biopure to seek approval for a trial of the cow-blood derivative on trauma patients outside of hospitals. Researchers want to test Hemopure in a mid- to late-stage trial that would test the safety and effectiveness of the therapy on patients suffering acute blood loss. The blood derivative is designed to be stored at room temperature and remain viable for years.

- read this AP report for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.